ESC 365 - Evolution of low risk natriuretic peptide to higher risk - Do we have a phenotype?

HFA Premium Access

Evolution of low risk natriuretic peptide to higher risk - Do we have a phenotype?

Session: Rapid Fire 2 - Biomarker: present and future

Topic: Prevention

Speaker: Doctor N. Blake (Dublin, IE)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Nial Blake

Mater Private Hospital, Dublin (Ireland)

0 follower

10 more presentations in this session

Role of neprilysin in myocardial tissue Renin-Angiotensin-System (RAS) of the failing heart

Speaker: Doctor N. Pavo (Vienna, AT)

The value of tubular maximum phosphate reabsorption capacity, a functional proximal tubular parameter in heart failure

Speaker: Ms L. Emmens (Groningen, NL)

The risk of bias of current novel circulating biomarker studies for the detection of HFpEF and left ventricular diastolic dysfunction

Speaker: Mr M. Henkens (Maastricht, NL)

The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients

Speaker: Doctor R. Nielsen (Aarhus, DK)

Improvement of existing strategies to prevent heart failure after myocardial infarction: a potential role for thrombopoietin

Speaker: Associate Professor L. Malinova (Saratov, RU)

Access the full session

Rapid Fire 2 - Biomarker: present and future

Speakers: Doctor N. Blake, Doctor N. Pavo, Ms L. Emmens, Mr M. Henkens, Doctor R. Nielsen...

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources